Neuphoria Therapeutics Financials - Benzinga

Neuphoria Therapeutics Inc

NEUPNASDAQ

Trade with Public

Trade with Public

$3.93

-0.0499-1.25%

Últ. Act.: Aug 19, 3:12 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Informe de acciones

Neuphoria Therapeutics Financials

Neuphoria Therapeutics (NEUP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Neuphoria Therapeutics Q3 EPS $(0.09) Beats $(0.97) Estimate

Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.97) by 90.72 percent. This is a 101.37 percent decrease over earnings of $6.55 per

Benzinga Newsdesk

Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings

Avi Kapoor

US Stocks Mixed; Coca-Cola Posts Upbeat Earnings

Avi Kapoor

PRO
Neuphoria Therapeutics Q4 EPS $(3.98) Misses $(2.08) Estimate, Sales $(13.267K)

Benzinga Newsdesk

PRO
Neuphoria Therapeutics Q1 EPS $6.55 Up From $(2.83) YoY, Sales $15.00M

Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly earnings of $6.55 per share. This is a 331.45 percent increase over losses of $(2.83) per share from the same period last year. The company reported $15.00 million

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved